These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 25123562

  • 1. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
    Hongo M, Miyakoshi N, Kasukawa Y, Ishikawa Y, Shimada Y.
    J Bone Miner Metab; 2015 Jul; 33(4):432-9. PubMed ID: 25123562
    [Abstract] [Full Text] [Related]

  • 2. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
    Takakuwa M, Iwamoto J.
    Biol Pharm Bull; 2012 Jul; 35(7):1159-65. PubMed ID: 22791166
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.
    Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K.
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.
    Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H.
    Osteoporos Int; 2011 Oct; 22(10):2735-42. PubMed ID: 21104227
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
    Tanaka S, Yoshida A, Kono S, Ito M.
    J Orthop Sci; 2017 May; 22(3):536-541. PubMed ID: 28108224
    [Abstract] [Full Text] [Related]

  • 10. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.
    Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    J Bone Miner Metab; 2009 Feb; 27(2):168-74. PubMed ID: 19183836
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 15. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun 20; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD, Farahmand P, Faber H, Dorst A.
    Rheumatol Int; 2009 Jan 20; 29(3):311-5. PubMed ID: 18762944
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M.
    J Orthop Sci; 2002 Jan 20; 7(6):637-43. PubMed ID: 12486466
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.